Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|April 20, 2026
Mechanisms of Acquired Resistance Following Dual EGFR/MET Inhibition in MET-Amplified EGFR TKI-Resistant Lung CancerYen-Ting Lin, Yi-Nan Liu, Ya-Chieh Hsu, et al.
Physical Review Letters|August 12, 2025
Intervalley Coherent Order in Rhombohedral Tetralayer Graphene on MoS_{2}Wei-Yu Liao, Wen-Xiao Wang, Shihao Zhang, et al.
The Oncologist|May 26, 2019
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR InhibitorsJih-Hsiang Lee, Hsuan-Yu Chen, Feng-Ming Hsu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 7, 2019
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patientsZong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, et al.
The Oncologist|May 17, 2017
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line GefitinibZong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, et al.
The Journal of Pathology|August 19, 2014
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancerWei-Yu Liao, Chao-Chi Ho, Hsin-Han Hou, et al.
Psycho-Oncology|February 25, 2018
Trajectories of caregiver burden and related factors in family caregivers of patients with lung cancerYun-Hsiang Lee, Yu-Chien Liao, Shiow-Ching Shun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2018
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use ProgramSolange Peters, Alessandra Curioni-Fontecedro, Hovav Nechushtan, et al.
Cancer Medicine|August 10, 2023
Oral uracil-tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early-stage non-small cell lung cancer patientsSheng-Kai Liang, Chang-Wei Wu, Ching-I Chang, et al.
International Journal of Cancer|November 29, 2018
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutationsYen-Ting Lin, Jin-Shing Chen, Wei-Yu Liao, et al.
Pageof 9